|
1
|
Howlader N, Noone AM, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2011, National Cancer
Institute. Bethesda, MD: based on November 2015 SEER data
submission. http://seer.cancer.gov/archive/csr/1975_2011/Accessed.
December 17–2018
|
|
2
|
Geng B, Liang MM, Ye XB and Zhao WY:
Association of CA 15–3 and CEA with clinicopathological parameters
in patients with metastatic breast cancer. Mol Clin Oncol.
3:232–236. 2015.PubMed/NCBI
|
|
3
|
Ideo H, Hinoda Y, Sakai K, Hoshi I,
Yamamoto S, Oka M, Maeda K, Maeda N, Hazama S, Amano J and
Yamashita K: Expression of mucin 1 possessing a 3′-sulfated core1
in recurrent and metastatic breast cancer. Int J Cancer.
137:1652–1660. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Donepudi MS, Kondapalli K, Amos SJ and
Venkanteshan P: Breast cancer statistics and markers. J Cancer Res
Ther. 10:506–511. 2014.PubMed/NCBI
|
|
5
|
Kirchhoff C, Habben I, Ivell R and Krull
N: A major human epididymis-specific cDNA encodes a protein with
sequence homology to extracellular proteinase inhibitors. Biol
Reprod. 45:350–357. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galgano MT, Hampton GM and Frierson HF Jr:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
|
|
7
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
8
|
Bingle L, Cross SS, High AS, et al: WFDC2
(HE4): A potential role in the innate immunity of the oral cavity
and respiratory tract and the development of adenocarcinomas of the
lung. Respir Res. 7:612006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Neal RL, Nam KT, LaFleur BJ, et al:
Human epididymis protein 4 is up-regulated in gastric and
pancreatic adenocarcinomas. Hum Pathol. 44:734–742. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
The TNM Classification of Malignant
Tumours of the Union for International Cancer Control. Sobin LH,
Gospodarowicz MK and Wittekin C: (7th). Wiley-Blackwell. Hoboken:
2009.
|
|
11
|
World Health Organization (WHO).
Classification of Tumours of the Breast. Lakhani SR, Ellis IO,
Schnitt SJ, Tan PH and van de Vijver MJ: (4th). WHO Press.
2012.
|
|
12
|
Clinical practice guidelines for the use
of tumor markers in breast and colorectal cancer. Adopted on May
17, 1996 by the American Society of Clinical Oncology. J Clin
Oncol. 14:2843–2877. 1996.PubMed/NCBI
|
|
13
|
Molina R, Jo J, Filella X, Zanon G, Pahisa
J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, et al:
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast
cancer: Prognostic value. Breast Cancer Res Treat. 51:109–119.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
LeBleu VS, Teng Y, O'Connell JT, Charytan
D, Müller GA, Müller CA, Sugimoto H and Kalluri R: Identification
of human epididymis protein-4 as a fibroblast-derived mediator of
fibrosis. Nat Med. 19:227–231. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferraro S, Braga F, Lanzoni M, Boracchi P,
Biganzoli EM and Panteghini M: Serum human epididymis protein 4 vs
carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic
review. J Clin Pathol. 66:273–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhen S, Bian LH, Chang LL and Gao X:
Comparison of serum human epididymis protein 4 and carbohydrate
antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin
Oncol. 2:559–566. 2014.PubMed/NCBI
|
|
17
|
Kamei M, Yamashita S, Tokuishi K, Hashioto
T, Moroga T, Suehiro S, Ono K, Miyawaki M, Takeno S, Yamamoto S and
Kawahara K: HE4 expression can be associated with lymph node
metastases and disease-free survival in breast cancer. Anticancer
Res. 30:4779–4783. 2010.PubMed/NCBI
|
